Surprisingly, despite the vast amount of evidence gathered over the years and the approval of dual SRC/ABL kinase inhibitors to treat BCR-ABL-positive leukemias (22), to date no kinase inhibitor has yet been approved for the treatment of SRC-active solid malignancies. This evidence concerns the gene SRC and leukemia.